- BSE Sensex recovers 51 points, Nifty up by 14 pts, stocks to watch: Cadila, HindalcoCredit Suisse downgrades Cadila Healthcare shares as earnings disappointment'Neutral' on Cadila Healthcare shares, price target Rs 871Clinical trials of new drugs get fresh impetus as govt clears 55 proposals
At a time when not many corporates are venturing into the strife-torn state of J&K, Ahmedabad-based Cadila Pharmaceuticals is busy chalking out plans to expand its existing R100-crore facility in Jammu.
Speaking at the sidelines of the inauguration of the Indravadan A Modi memorial lecture series, Cadila CMD Rajiv I Modi said, “Our experience of setting up and running a facility at Jammu has been so good that we are now scouting for more land near our plant at Samba to expand and upgrade our business.” Apart from Cadila, pharma majors like Lupin and Sun Pharma, too, have plants in the area.
Cadila’s Samba facility commenced operations in 2006. The second formulations manufacturing facility of the company, after its formulations manufacturing plant at Dholka near Ahmedabad, has a workforce of 500 and meets most of the stringent global quality standards for production of tablets, capsules, gelatin capsules and orals.
The Jammu plant, which was initially set up in view of the tax incentives being offered by the J&K government, is now contributing around R300 crore to the company’s total turnover. Currently running just one shift, the plant is now being upgraded to cater to the thrust Cadila proposes to give to exports in the near future.
(Travel for this report was sponsored by Cadila)